Onxeo SA, which was formed from the 2014 merger of BioAlliance Pharma SA of France and Topotarget A/S of Denmark, has completed the acquisition of DNA Therapeutics SA of France in a move that will strengthen its expertise in rare cancers. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
